Elevation of the large bowel histamine concentration by aminoguanidine induced diamine oxidase inhibition.
In inflammatory diseases of the large bowel a reduced diamine oxidase activity was found which may be related to a reduced oxidative degradation of histamine. An experimental inhibition of diamine oxidase could therefore influence the large bowel histamine concentration. The diamine oxidase inhibitor aminoguanidine was administered to rats in a single dose of 100 mg/kg orally, i.v., or i.p. A rapid increase of the concentration of the drug in the large bowel was measured (half-life = 2-5 h). During chronic amino-guanidine administration (3 times/week, 100 mg/kg orally) the large bowel histamine increased by 30% on average. This may be sufficient for a proliferative stimulus of the intestinal mucosa. Previous reports of an increase of body weight of animals and of patients under aminoguanidine treatment could not be confirmed by our study.
D000284:Administration, Oral; D006631:Amine Oxidase (Copper-Containing) / Q000037:antagonists & inhibitors*; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D006146:Guanidines / Q000008:administration & dosage / Q000494:pharmacology*; D006632:Histamine / Q000032:analysis*; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007420:Intestine, Large / Q000032:analysis / Q000187:drug effects*; D008297:Male; D051381:Rats; D011916:Rats, Inbred F344
D006146:Guanidines; D006632:Histamine; D006631:Amine Oxidase (Copper-Containing); C004479:pimagedine